{"height":"190","type":"rich","published":"2017-01-31 00:00:02","version":"1.0","categories":["EFSA"],"provider_name":"Hatena Blog","provider_url":"https://hatena.blog","image_url":null,"url":"https://uneyama.hatenadiary.jp/entry/20170131/p3","blog_title":"\u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b","author_name":"uneyama","blog_url":"https://uneyama.hatenadiary.jp/","description":"\u2018Nutrimune\u00ae\u2019\u3068\u80c3\u8178\u53ca\u3073\u4e0a\u6c17\u9053\u306e\u75c5\u539f\u83cc\u306b\u5bfe\u3059\u308b\u514d\u75ab\u9632\u5fa1\uff1a\u5065\u5eb7\u5f37\u8abf\u8868\u793a \u2018Nutrimune\u00ae\u2019 and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 EFSA Journal 2017;15(1):4679 [14 pp.]. 30 January 2017 https://www.efsa.\u2026","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Funeyama.hatenadiary.jp%2Fentry%2F20170131%2Fp3\" title=\"\u610f\u898b\u7b49 - \u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","width":"100%","title":"\u610f\u898b\u7b49","author_url":"https://blog.hatena.ne.jp/uneyama/"}